Nuformix PLC Nuformix Commences NXP001 Clinical Trial (6499T)
March 22 2019 - 3:00AM
UK Regulatory
TIDMNFX
RNS Number : 6499T
Nuformix PLC
22 March 2019
Nuformix plc
("Nuformix" or the "Company")
Nuformix Commences NXP001 Clinical Trial
First patient dosed with Nuformix cocrystal product
Cambridge, UK, 22 March 2019: Nuformix (LSE: NFX), the
pharmaceutical development company using cocrystal technology to
unlock the therapeutic potential of approved small molecule drugs,
announces it has commenced clinical studies for the Company's lead
asset NXP001.
NXP001 is in development as a treatment for chemotherapy-induced
nausea and vomiting ("CINV"), a large, under-exploited and growing
market, which in demographic terms comprises one third of global
cancer patients.
First dosing of NXP001 took place successfully on 20 March 2019
in a cross-over study that aims to measure the relative
bioavailability of NXP001 compared to Merck's EMEND(R) in healthy
subjects. Dosing will complete during April 2019 with results
expected by end H1 2019.
The data gathered from the trial will enable the Company to:
-- Confirm NXP001's suitability for rapid development as a treatment for CINV, allowing current and future licensees
to launch new products into the GBP16bn oncology supportive care market
-- Trigger a final milestone payment of GBP2m from its Chinese licensing partner, Newsummit Biopharma, and proceed
with product registration process in China (Nuformix retains 10% royalty)
-- Progress on-going discussions for licensing rest of world rights to NXP001 for CINV
-- Substantiate further product development opportunities for the NXP001 programme to generate significant
additional future value
-- Validate its underlying strategy, technology and IP by rapidly generating clinical data in a cost-effective
manner to support out-licensing activities and generate revenue
Dr Dan Gooding, CEO, Nuformix plc, said: "The initiation of
clinical studies for NXP001 marks a critical milestone for
Nuformix, not just as a measure of the progress the Company has
made, but also due to the associated technical and commercial
significance. The results from the study will trigger payment of
the final GBP2m milestone from Newsummit Biopharma and advance
product registration in China.
"From on-going discussions with additional licensing partners,
we believe that NXP001 can address key issues that currently
restrict patient access to highly efficacious treatment for their
CINV. Data confirming Nuformix's patented approach as a solution to
CINV applications is the final piece in the validation of our
technology, increasing Nuformix's ability to conclude further
commercial partnerships globally."
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 627222
Optimum Strategic Communications
Mary Clark, Supriya Mathur +44 (0) 203 950
Email: nuformix@optimumcomms.com 9144
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio of granted patents covering
cocrystal forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
About NXP001
Nuformix is developing NXP001 as a treatment for
chemotherapy-induced nausea and vomiting ("CINV"). NXP001 is
cocrystal-based product containing the NK-1 antagonist, aprepitant.
Aprepitant is the active ingredient in Emend(R) (Merck) marketed
globally for the treatment of CINV. CINV is a large,
under-exploited and growing market, which in demographic terms
comprises one third of global cancer patients. NXP001 will enable
new product entries into the oncology supportive care market,
currently valued at over GBP16bn.
About EMEND(R)
EMEND(R) (aprepitant, NK-1 antagonist) was developed by Merck
and is approved worldwide for the treatment of CINV and
post-operative nausea and vomiting (PONV). The NK1-based treatment
regimen is globally recognised as the most efficacious in treating
CINV and is first-line therapy according to NCCN and NICE
guidelines for all highly emetogenic chemotherapy agents.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESLLFFDVFILFIA
(END) Dow Jones Newswires
March 22, 2019 03:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2023 to Apr 2024